California encephalitis virus
|California encephalitis virus|
|Group:||Group V ((-)ssRNA)|
|Species:||California encephalitis virus|
|California encephalitis virus|
|Classification and external resources|
California encephalitis virus was discovered in Kern County, California and causes encephalitis in humans. Encephalitis is an acute inflammation of the brain that can cause minor symptoms, such as headaches, to more severe symptoms such as seizures. Mosquitoes serve as its carrier and for this reason this virus is known as an arbovirus (arthropod-borne virus).
California encephalitis virus belongs to the Bunyaviridae family of viruses. The La Crosse Virus is a common cause of encephalitis in the United States. Other viruses with similar disease symptoms but genetically unrelated include: St. Louis Encephalitis and West Nile Virus.
It was first discovered and isolated in 1943, from mosquitoes collected in Kern County, California. Two years later the first human cases of encephalitis were attributed to this new virus. Three cases in total were reported, and all three cases were in residents of Kern County in the Central Valley of California. In all three cases there was strong laboratory evidence confirming infection, due to the presence of neutralizing antibodies linked to California encephalitis. Since then, most cases of encephalitis have been associated with the La Crosse virus, and California encephalitis is a rare cause of disease in the Western World.
The original California Encephalitis virus was isolated and put alongside fifteen other related viruses that are now categorized as the California serogroup. From 1996 to 1998, approximately three times as many reported human cases of arboviral encephalitis were caused by California serogroup viruses than were reported for western equine encephalomyelitisviruses, St. Louis encephalitis, and eastern equine encephalomyelitis viruses combined.
In the United States several factors influence the transmission and control of diseases of arboviral encephalitis, like those of the California Encephalitis virus. These factors include: the season, geographical location, patient age, and the regional climate condition such as spring or rainfall. There are approximately 75 cases reported per year. The highest occurrence of arboviral encephalitis in the United States is in the Midwestern states, with most cases occurring in the late summer to early fall. Outdoor activities, especially in woodland areas, are associated with an increased risk of infection.
Mortality rates are less than 1% and most patients with encephalitis clinical symptoms recover completely; however, 20% of patients develop behavioral problems or recurrent seizures. Encephalitis disease in general occurs almost exclusively in children from 6 months to 16 years old.
Initial infection by the virus and primary spread of the virus causes the onset of non-specific symptoms such as headache and fever. Secondary spread and the multiplication of the virus in the CNS (central nervous system) causes symptoms such as stiff neck, lethargy and seizures. It then can result in encephalitis, when inflammation of the brain, produced by infection by the virus, damages nerve cells, which affects signaling of the brain to the body.
After the virus enters the body via a mosquito bite, the virus undergoes local replication at the skin site where virus entered the body. A primary spread of virus occurs, with seeding of the reticuloendothelial system, mainly in the liver, spleen, and lymph nodes. With the ongoing replication of the virus a secondary spread occurs, with the seeding of the CNS. Not all the cases reach this stage, depending on the efficiency of viral replication at the different stages and the degree of virus spread. The California encephalitis virus invades the CNS through either the cerebral capillary endothelial cells or the choroid plexus.
The incubation period of California encephalitis is usually 3–7 days. An early symptoms phase of 1–4 days commonly precedes the onset of encephalitis. This phase manifests as fever, chills, nausea, vomiting, headache, and abdominal pain.
The encephalitis is characterized by fever, drowsiness, and lack of mental alertness and orientation. Seizures occur in 50% of children. Focal neurologic signs such as irregular and abnormal reflexes develop in 20% of children. 10% of patients develop coma. The total duration of illness rarely exceeds 10–14 days. Recurrent unprovoked seizures occur even after the illness has passed develops in 20% of patients, especially those who had seizures during the acute illness. In adults, infection is asymptomatic, which means that the patient is a carrier of the infection, but experiences no symptoms or only mild feverish illness.
The symptoms include: fever, lethargy, focal neurologic findings, focal motor abnormalities and paralysis.
Treatments are given to manage the symptoms the patient is having. In patients who are very sick, supportive treatment, such as mechanical ventilation, is equally important. Steroids are used to reduce brain swelling and inflammation. Sedatives may be needed for irritability or restlessness. Acetaminophen is used for fever and headache. Anticonvulsants are used to prevent seizures. If brain function is severely affected, interventions like physical therapy and speech therapy may be needed after the illness is controlled.
La Crosse virus (LACV)-mediated encephalitis is the most frequently reported arboviral disease in the United States, but to date no vaccine against this virus is available. California encephalitis is caused by a group of viruses called the California group virus. These viruses are transmitted to humans by mosquitoes.This encephalitis and related infections are transmitted by mosquitoes and occur in the US Midwest and probably worldwide. No treatment is available, thus the urgency in developing a vaccine.. La Crosse. California serogroup viruses including California encephalitis, Keystone, La Crosse, Jamestown Canyon, snowshoe hare, and trivittatus are all mosquito-borne arboviral infections. In the United States, La Crosse virus (LACV) is the most common of the California serogroup viruses. Mice show an age-independent susceptibility to LACV and develop an acute encephalitis within 6 days of infection, thereby allowing the evaluation of vaccines against LACV. Plasmid DNAs, encoding either the virus surface glycoproteins G1 and G2 or the internal nucleocapsid protein N, were used to immunize IFNAR-1-deficient mice. Mice vaccinated with DNA encoding the glycoproteins G1 and G2 produced neutralizing antibodies and exhibited a high degree of protection against challenge with high doses of LACV. Depletion of CD4+ T cells in mice vaccinated with DNA encoding G1/G2 reduced their capacity to control the infection. Thus, DNA vaccines can be designed to efficiently induce a protective immune response based on neutralizing antibodies and CD4+ T cells.
- Hammon, W. M.; Reeves, W. C. (November 1952). "California Encephalitis Virus, a Newly Described Agent" (pdf). California Medicine 77 (5): 303–309. PMC 1521486. PMID 13009479.
- Anderson, W. E.; Soliman, E.; Perez, N.; Gotuzzo, E. (2011-07-17). "California Encephalitis". Medscape Reference. WebMD. Retrieved 2012-02-25.
- Eldridge, B. F.; Glaser, C.; Pedrin, R. E.; Chiles, R. E. (March 2009). "The First Reported Case of California Encephalitis in More Than 50 Years" (pdf). Emerging Infectious Diseases 7 (3): 451–452. PMC 2631795. PMID 11384526.
- Kaneshiro, N. K. (2010-07-26). "Encephalitis". Times Health Guide. The New York Times. Retrieved 2012-02-25.